Every Form 4 that Recursion Pharmaceuticals, Inc. (RXRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXRX filings page.
RECURSION PHARMACEUTICALS, INC. (RXRX) director Blake Borgeson sold shares of the company’s Class A Common Stock. On September 1, 2026, he sold 30,000 shares at an average price of $3.34 per share in an open-market or private transaction. Following this sale, he continued to hold 6,158,287 shares of Class A Common Stock directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025, indicating the transaction was pre-arranged under that plan.
RECURSION PHARMACEUTICALS, INC. (RXRX) reported that CEO and President Najat Khan had 80,498 shares of Class A Common Stock withheld on 2026-08-17. These shares were withheld by the company to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units, not sold in an open-market transaction. After this withholding, Khan directly holds 2,095,298 shares of Class A Common Stock.
RECURSION PHARMACEUTICALS, INC. (RXRX) reported that Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on 2026-08-17 to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units. This reduced his position for tax purposes only; his direct holdings after this event are 1,043,837 shares of Class A common stock.
RECURSION PHARMACEUTICALS, INC. (RXRX) reported that its Chief Financial Officer, Ben R. Taylor, had 25,018 shares of Class A Common Stock withheld on 2026-08-17 to satisfy tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This tax-withholding disposition was recorded at $3.16 per share, and Taylor now directly holds 1,076,858 shares of Class A Common Stock.
Recursion Pharmaceuticals, Inc. director Blake Borgeson reported selling 30,000 shares of Class A Common Stock on August 4, 2026 at $3.25 per share in an open-market or private transaction pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025, and now directly holds 6,188,287 shares.
RECURSION PHARMACEUTICALS, INC. director Blake Borgeson reported an open-market sale of Class A common stock. On July 7, 2026, he sold 40,000 shares at a weighted average price of about $3.96 per share. After this transaction, he directly holds 6,218,287 shares of the company.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025. The shares were sold in multiple trades at prices ranging from $3.95 to $4.00, with the reported price reflecting the weighted average sale price.
Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Zavain Dar received an award of 5,109 shares of Class A Common Stock. The shares were issued at no cash cost to him and were granted under the company’s Outside Director Compensation Policy. Following this award, he directly holds 240,764 Class A shares.
Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Dean Y. Li reported an equity award of Class A Common Stock. He received 3,747 shares at $0.0000 per share as compensation under the company’s Outside Director Compensation Policy, increasing his direct holdings to 1,473,329 Class A shares.
In addition to these direct holdings, he is also shown as indirectly holding 421,000 Class A shares through the Dean Y. Li 2021 Family Trust and 1,422,048 Class A shares through the Dean Y. Li Revocable Trust.
Borgeson Blake reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Blake Borgeson received a grant of 88,424 shares of Class A common stock in the form of restricted stock units under the company’s Outside Director Compensation Policy. These units vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholder meeting, subject to his continued service. Following this award, he directly holds 6,258,287 shares.
HERSHBERG ROBERT reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Robert Hershberg received an equity grant of 88,424 shares of Class A Common Stock in the form of restricted stock units. The grant was made at no cash cost under the company’s Outside Director Compensation Policy as a routine award.
These restricted stock units vest on the earlier of June 17, 2027 or the day before the company’s 2027 annual stockholder meeting, contingent on his continued service. Following this grant, Hershberg directly holds 162,156 shares reported as beneficially owned.
Michor Franziska reported acquisition or exercise transactions in this Form 4 filing.
Recursion Pharmaceuticals director Franziska Michor received a grant of 88,424 restricted stock units of Class A Common Stock as compensation under the company’s Outside Director Compensation Policy. The units were granted at $0.00 per share, reflecting a stock-based award rather than an open-market purchase.
The restricted stock units will vest on the earlier of June 17, 2027 or the day prior to Recursion’s 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, Michor directly holds 215,477 shares of the company’s Class A Common Stock.
Sun Elaine D reported acquisition or exercise transactions in this Form 4 filing.
Recursion Pharmaceuticals director Elaine D. Sun received an equity award of 88,424 shares of Class A Common Stock in the form of restricted stock units. The award was granted at no cash cost to her under the company’s Outside Director Compensation Policy.
The restricted stock units will vest on the earlier of June 17, 2027 or the day before Recursion’s 2027 Annual Meeting of Stockholders, provided she continues serving the company. Following this grant, Sun directly holds 135,981 shares of Class A Common Stock.
Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS director Zavain Dar received an equity grant. He was awarded 88,424 shares of Class A Common Stock in the form of restricted stock units for board service, at no cash cost. These RSUs vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholder meeting, subject to continued service, bringing his direct holdings to 235,655 shares.
Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Dean Y. Li reported an equity award and updated holdings in Class A Common Stock. He received a grant of 88,424 restricted stock units, automatically granted under the company’s Outside Director Compensation Policy, at a stated price of $0.00 per share.
The restricted stock units will vest on the earlier of June 17, 2027 or the day prior to the company’s 2027 Annual Meeting of Stockholders, as long as he continues to serve the company. Following this award, Li holds 1,469,582 shares directly, plus indirect holdings through the Dean Y. Li 2021 Family Trust and the Dean Y. Li Revocable Trust.
RECURSION PHARMACEUTICALS, INC. director Namandje Bumpus reported both an equity award and a small share sale. On June 17, 2026, Bumpus received a grant of 88,424 restricted stock units under the company’s Outside Director Compensation Policy. These units vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholders’ meeting, subject to continued service.
On June 18, 2026, Bumpus sold 3,963 shares of Class A Common Stock in an open‑market transaction at $3.18 per share, executed under a Rule 10b5‑1 trading plan adopted on March 3, 2026. After the reported transactions, Bumpus directly owned 127,632 shares of Class A Common Stock.
Recursion Pharmaceuticals Chief Financial Officer Ben R. Taylor reported a tax-related share disposition. On this Form 4, 5,396 shares of Class A Common Stock were withheld at $3.15 per share to satisfy tax withholding and remittance obligations tied to net settlement of restricted stock units. After this transaction, Taylor directly owns 1,101,876 shares of Class A Common Stock.
Recursion Pharmaceuticals director Christopher Gibson reported converting 40,000 shares of Class B Common Stock into Class A Common Stock on June 5, 2026, and selling 40,000 Class A shares at $3.6200 per share in a transaction reported as pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. After these trades, he reported holding 883,735 shares of Class A Common Stock directly.
Recursion Pharmaceuticals CEO and President Najat Khan reported an open-market sale of 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025.
After this sale, Khan directly holds 2,175,796 shares, indicating she retains a substantial ownership stake in the company while taking limited liquidity through this planned transaction.
RECURSION PHARMACEUTICALS director Namandje Bumpus sold shares in a pre-planned trade. On this Form 4, Bumpus reported an open-market sale of 4,386 shares of Class A common stock at an average price of $3.54 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, Bumpus directly holds 43,171 shares of Recursion Pharmaceuticals, so the sale reflects only a portion of the director’s overall stake.
Recursion Pharmaceuticals director Blake Borgeson sold shares in a planned trade. On June 2, he executed an open-market sale of 30,000 shares of Class A Common Stock at $3.68 per share. After the sale, he directly holds 6,169,863 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 31, 2025.
RECURSION PHARMACEUTICALS director Christopher Gibson converted and sold shares in a planned set of transactions. On May 22, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold those 40,000 Class A shares in an open-market transaction at $3.08 per share. The filing notes the activity was carried out under a Rule 10b5-1 trading plan adopted on May 12, 2025, indicating the trades were pre-scheduled. After these moves, he directly holds 883,735 Class A shares and 4,303,334 Class B shares, with each Class B share convertible into one Class A share.
Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported a tax-related share disposition. On this Form 4, 26,657 shares of Class A Common Stock were withheld at a price of $3.04 per share to cover tax obligations tied to restricted stock units.
These shares were retained by the company to satisfy withholding and remittance duties in connection with net-settled RSUs, not sold on the open market. After this withholding event, Hallett directly holds 1,070,494 shares of Class A Common Stock.
RECURSION PHARMACEUTICALS, INC. CEO and President Najat Khan reported a routine tax-related share disposition. On this Form 4, 62,701 shares of Class A Common Stock were withheld at $3.04 per share to satisfy tax withholding and remittance obligations tied to the net settlement of restricted stock units, rather than being sold on the open market. Following this withholding, Khan directly holds 2,199,384 shares of Class A Common Stock.
RECURSION PHARMACEUTICALS, INC. Chief Financial Officer Ben R. Taylor reported a tax-related share disposition. On this Form 4, 25,018 shares of Class A Common Stock were withheld at $3.04 per share to satisfy tax obligations from net-settled restricted stock units. This was not an open-market sale. After the withholding, Taylor directly owns 1,107,272 Class A shares.
Recursion Pharmaceuticals director Christopher Gibson reported a routine tax-withholding transaction involving Class A Common Stock. On the reported date, 22,821 shares of Class A Common Stock were withheld at $3.04 per share to satisfy tax obligations from the net settlement of restricted stock units, rather than through an open-market sale.
After this withholding, Gibson directly held 883,735 Class A Common shares. The filing also lists various stock option grants with exercise prices between $2.48 and $11.40 per share and expirations from 2030 to 2035, as well as Class B Common Stock held indirectly through the Gibson Family Trust and LAHWRAN-3 and LAHWRAN-4 LLCs.
Recursion Pharmaceuticals director Christopher Gibson reported multiple stock movements in Class A and Class B shares. He sold 40,000 shares of Class A Common Stock at $3.37 per share in an open-market transaction and made a bona fide gift of 20,000 shares, both on May 7, 2026, under a pre-arranged Rule 10b5-1 trading plan. He also converted 60,000 shares of Class B Common Stock into 60,000 shares of Class A Common Stock. After these transactions, he directly holds 906,556 shares of Class A Common Stock. The filing also lists several outstanding stock option awards with exercise prices between $2.48 and $10.09, expiring between 2030 and 2035, and indirect holdings of Class B shares through family entities.
RECURSION PHARMACEUTICALS, INC. director Blake Borgeson completed an open-market sale of 30,000 shares of Class A Common Stock at $3.52 per share. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025. Following this sale, Borgeson directly owns 6,199,863 shares of Class A Common Stock, so the transaction represents a small portion of his overall reported holdings.
Recursion Pharmaceuticals director Christopher Gibson reported an exercise-and-sell style transaction involving 40,000 shares of Class A Common Stock. He converted 40,000 shares of Class B Common Stock into 40,000 Class A shares and then sold 40,000 Class A shares in an open-market transaction at $3.61 per share.
According to a footnote, this activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Gibson on May 12, 2025. After these moves, he holds 906,556 Class A shares directly, along with 4,403,334 Class B shares directly and additional Class B shares held indirectly through family entities.
Recursion Pharmaceuticals CFO Ben R. Taylor reported a tax-related share disposition. On April 6, 2026, 48,028 shares of Class A Common Stock at $3.11 per share were withheld by the company to cover tax obligations from net settlement of restricted stock units. After this withholding, Taylor directly owns 1,132,290 shares of the company’s Class A Common Stock.
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock. On April 7, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock and then sold 40,000 Class A shares at $3.10 per share in an open-market transaction.
The trades were made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025. Following these transactions, he directly holds 906,556 shares of Class A Common Stock and 4,443,334 shares of Class B Common Stock, while various family entities no longer show Class B holdings in this filing.
Recursion Pharmaceuticals director Blake Borgeson reported an open-market sale of Class A Common Stock. On this transaction date, he sold 30,000 shares at a price of $3.10 per share. After the sale, he directly held 6,229,863 shares of Class A Common Stock.
The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Zavain Dar received a grant of 4,902 shares of Class A Common Stock. The shares were issued at no cash cost to him under the company’s Outside Director Compensation Policy and are reported as directly owned. Following this award, he holds 147,231 Class A shares.
Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Dean Y. Li received a grant of 3,268 shares of Class A Common Stock at $0.0000 per share. The shares were issued under the company’s Outside Director Compensation Policy, reflecting equity-based compensation rather than an open-market purchase.
Following this grant, Li directly owns 1,244,177 Class A shares. He also has indirect ownership through several entities, including the Dean Y. Li Revocable Trust, the Dean Y. Li GRAT, and the Dean Y. Li 2021 Family Trust, each with separately reported share balances.
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock. He converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold 40,000 Class A shares at $3.25 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan. Following these transactions, he holds 906,556 shares of Class A Common Stock and 4,483,334 shares of Class B Common Stock directly.
Recursion Pharmaceuticals Chief Financial Officer Ben R. Taylor reported routine share movements in company stock. On March 17, 2026, he completed an open-market sale of 7,956 shares of Class A Common Stock at $3.39 per share. On March 16, 2026, 7,075 shares were disposed to cover tax obligations tied to net settlement of restricted stock units, which is not an open-market trade. After these transactions, Taylor directly held 1,180,318 shares of Class A Common Stock. The open-market sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025, indicating the timing was planned in advance.
Recursion Pharmaceuticals director Christopher Gibson converted 20,000 shares of Class B Common Stock into 20,000 shares of Class A Common Stock on March 9, 2026. The conversion price was reported as $0.00 per share.
On the same date, he made a bona fide gift of 20,000 Class A shares, leaving him with 906,556 Class A shares directly owned and 4,523,334 Class B shares directly owned after these transactions.
RECURSION PHARMACEUTICALS, INC. CEO and President Najat Khan reported an open-market sale of 28,298 shares of Class A common stock on March 9, 2026 at a weighted average price of $3.3451 per share. The trades were executed at prices ranging from $3.32 to $3.405.
After this transaction, Khan directly holds 2,262,085 shares of Class A common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, indicating the timing was set in advance rather than decided opportunistically.
Recursion Pharmaceuticals director Blake Borgeson sold shares in an open-market transaction. On 2026-03-03, he sold 170,000 shares of Class A common stock at an average price of $3.46 per share. After this sale, he directly owns 6,259,863 shares of the company’s Class A common stock.
Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported a tax-withholding disposition of 11,908 shares of Class A Common Stock at $3.49 per share. The shares were withheld by the company to cover taxes on restricted stock units, leaving him with 1,097,151 shares held directly.
Recursion Pharmaceuticals director Christopher Gibson reported multiple share transactions. He converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold 40,000 Class A shares at $3.46 each under a Rule 10b5-1 trading plan. Separately, 27,265 Class A shares were disposed of to cover tax withholding on restricted stock units.
RECURSION PHARMACEUTICALS, INC. Chief Financial Officer Ben R. Taylor reported two transactions in Class A common stock. On February 18, 2026, he completed an open-market sale of 13,426 shares at $3.08 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 1,195,349 shares owned directly.
On February 17, 2026, 11,908 shares were disposed of at $3.49 per share to cover tax withholding in connection with the net settlement of restricted stock units. These shares were withheld by the company to satisfy tax obligations rather than sold for discretionary portfolio reasons.
Recursion Pharmaceuticals CEO Najat Khan reported a tax-related share disposition. On February 17, 2026, 14,280 shares of Class A common stock at $3.49 per share were withheld by the company to cover tax obligations tied to restricted stock units. After this withholding, Khan directly owned 2,290,383 shares of Class A common stock. This was a tax-withholding transaction, not an open-market buy or sell.
Recursion Pharmaceuticals, Inc. reported new equity awards to its CEO and President, Najat Khan. On February 6, 2026, Khan received 1,673,546 shares of Class A common stock for no cash cost through restricted stock units. An additional 30,346 RSU-based shares vested immediately on the grant date.
The large RSU grant vests in equal sixteenth portions, starting May 15, 2026 and then every three months. To cover taxes on these equity awards, 10,364 shares were withheld at a price of $3.98 per share. After these transactions, Khan directly owned 2,304,663 Class A common shares.
Recursion Pharmaceuticals’ Chief Financial Officer Ben R. Taylor reported equity compensation activity. On February 6, 2026, he received 446,279 Class A RSUs that vest in equal sixteenth installments starting May 15, 2026 and every three months afterward, plus 24,254 RSUs that vested immediately.
The company also withheld 11,400 shares at $3.98 per share to satisfy tax obligations from RSU settlement. After these transactions, Taylor directly beneficially owned 1,220,683 shares of Class A Common Stock.
Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported equity compensation transactions in Class A common stock. On February 6, 2026, he acquired 502,064 shares at $0 per share from a restricted stock unit (RSU) grant that vests in sixteenth installments starting May 15, 2026 and every three months thereafter. He also acquired 24,254 shares at $0 per share from an RSU that vested immediately on the grant date. On the same day, 11,400 shares were withheld at $3.98 per share to cover tax obligations related to RSU settlement. After these transactions, Hallett directly owned 1,109,059 Class A shares.
Recursion Pharmaceuticals director Christopher Gibson reported several stock transactions in early February 2026. On February 4, he converted 40,000 shares of Class B Common Stock into Class A at $0 per share, then sold 40,000 Class A shares at $4.12 under a pre-arranged Rule 10b5-1 trading plan.
On February 6, Gibson received 30,346 Class A shares from restricted stock units that vested immediately at $0, and 10,364 shares were withheld at $3.56 to cover taxes. After these transactions, he directly held 933,821 Class A shares, alongside sizable option and convertible Class B positions.
Recursion Pharmaceuticals director Blake Borgeson sold 220,000 shares of Class A common stock on February 3, 2026 at $4.20 per share. The sale was made under a Rule 10b5-1 trading plan adopted on August 31, 2025. After this transaction, he beneficially owned 6,429,863 shares, held directly.
Recursion Pharmaceuticals director Christopher Gibson reported a planned share sale and related conversion. On January 20, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock at $0 per share pursuant to the Class B conversion feature. The same day, he sold 40,000 Class A shares at $4.47 per share under a Rule 10b5-1 trading plan adopted on May 12, 2025.
After these transactions, Gibson directly owned 913,839 shares of Class A Common Stock. He also reported additional indirect Class A holdings through entities he manages or serves as trustee, including 386,000 shares via LAHWRAN-3 LLC, 388,000 shares via LAHWRAN-4 LLC, and 50,000 shares via the Gibson Family Trust, as well as multiple outstanding stock options with various exercise prices and expirations.
Recursion Pharmaceuticals director Blake Borgeson reported selling 220,000 shares of the company’s Class A common stock on January 6, 2026 at a price of $4.36 per share. After this transaction, he beneficially owned 6,649,863 shares of Class A common stock in direct ownership.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule or conditions, helping separate routine liquidity transactions from day-to-day market or company developments.
Recursion Pharmaceuticals director Christopher Gibson reported several share moves on January 5, 2026. He converted 60,000 shares of Class B Common Stock into 60,000 shares of Class A Common Stock at a stated price of $0, then sold 40,000 Class A shares at $4.25 per share and made a gift of 20,000 Class A shares. After these transactions, he directly held 913,839 shares of Class A Common Stock.
The filing also shows he directly holds 4,663,334 shares of Class B Common Stock, each convertible into one Class A share, and additional Class B holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust. Multiple stock options to buy Class A shares remain outstanding with exercise prices ranging from $2.48 to $11.40 and expirations between 2030 and 2035. The conversion, sale, and gift were made under a Rule 10b5-1 trading plan adopted on May 12, 2025.